Search Results
Your search for The ASCO ,The ASCO matches 20588 pages
Showing 8201 - 8250
Matthew B. Schabath, PhD, on Addressing Cultural Barriers to Equality in Oncology Among Sexual and Gender Minorities
Matthew B. Schabath, PhD, of H. Lee Moffitt Cancer Center and Research Institute, discusses the disparities in cancer care among members of the LGBTQ community and the need to collect more data in order to close that gap.
Angela M. Stover, PhD, on Patient-Reported Outcome Performance Measures for Oncology Practice
Angela M. Stover, PhD, of the University of North Carolina at Chapel Hill, discusses ASCO’s initiative to develop patient-based performance measures for assessing and managing symptoms. The measures have made substantial differences in reducing nausea, constipation, and insomnia (Abstract 173).
Lauren M. Hamel, PhD, on Race and Doctor-Patient Behavior
Lauren M. Hamel, PhD, of Wayne State University/Karmanos Cancer Institute, discusses her findings on the ways in which nonverbal behavior between doctors and patients of the same or different races can affect their relationship, quality of communication, and ultimately, perhaps outcomes as well...
Mallika Sharma, MPH, on Eliminating Prior Authorizations, Anxiety, Delay in Care, Higher Costs
Mallika Sharma, MPH, of Seattle Cancer Care Alliance, discusses her findings that, by doing away with the many prior authorization denials based on administrative errors, providers may offer higher-value care by eliminating unnecessary anxiety among patients, administrative burdens, and increased...
Grace C. Hillyer, EdD, MPH, on Enrolling Patients in Clinical Trials: Improving Clinician-Patient Communication
Grace C. Hillyer, EdD, MPH, of Columbia University Mailman School of Public Health, discusses the many barriers to enrolling patients in clinical trials, most notably different attitudes toward and perceptions about research studies among clinicians vs patients. Her findings point to the need for...
Elena Martinez, PhD, MPH, on Diversity in Precision Oncology
Elena Martinez, PhD, MPH, of Moores Cancer Center at the University of California, San Diego, discusses the challenges of ensuring diversity in precision oncology and potential solutions to address the challenges.
Oncology Communications Online: Pause and Think Before Hitting ‘Send’
The emergence of online technologies over the past few decades has fundamentally changed the way society communicates and shares information. This sea change has also had profound influence on the practice of medicine, from real-time information-sharing among colleagues, to having instant access...
Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials
Ryan Huey, MD, of The University of Texas MD Anderson Cancer Center, discusses his findings that showed the large financial burden on lower-income patients enrolled in phase I trials (Abstract 8).
Cristina Merkhofer, MD, MHS, on NSCLC: Survival Impact of Taking Part in a Clinical Trial
Cristina Merkhofer, MD, MHS, of Fred Hutchinson Cancer Research Center, discusses study results showing that for patients with metastatic non–small cell lung cancer at her institution, enrolling in a therapeutic drug clinical trial was associated with a 47% lower risk of death, compared with not...
Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival
Bernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive...
WCLC 2019: Screening Efficacy of PLCOm2012 vs USPSTF Criteria
Researchers reported that a prospective trial comparing two screening methods for patients at risk of developing lung cancer found that a model used by Canadian, Australian, and European public health organizations detected more cancers than the screening model used by the United States Preventive...
Olaparib Monotherapy Improves Outcomes in BRCA-Mutated, Platinum-Sensitive Relapsed Ovarian Cancer
Compared with treatment with nonplatinum-based chemotherapy, monotherapy with the PARP (poly [ADP ribose] polymerase) inhibitor olaparib led to statistically significant and clinically relevant improvements in overall response rate and progression-free survival in women with germline...
WCLC 2019: Survey Findings on Evidence-Based Guidelines for Molecular Testing in Lung Cancer
One-third of those who responded to a survey reported they are unaware of evidence-based guidelines that support the use of molecular testing in lung cancer, according to results from the International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung...
2019 Lasker Awards for Basic and Clinical Medical Research and Public Service Announced
On September 10, The Lasker Foundation announced the winners of its 2019 Lasker Awards: Max D. Cooper, MD, of Emory University, and Jacques Miller, AC, FRS, FAA, of the Walter and Eliza Hall Institute of Medical Research, will receive the Albert Lasker Basic Medical Research Award; H. Michael...
WCLC 2019: CASPIAN Trial Finds Addition of Durvalumab to Chemotherapy Improves Overall Survival in Patients With Extensive-Stage SCLC
The addition of durvalumab to chemotherapy improved overall survival in patients with extensive-stage small cell lung cancer (SCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) (Abstract PL02.11)....
WCLC 2019: Pooled Analysis of CheckMate 017 and 057: 5-Year Outcomes With Nivolumab vs Docetaxel in Previously Treated NSCLC
Pooled data on two clinical trials demonstrated patients with previously treated non–small cell lung cancer (NSCLC) treated with nivolumab had a greater than fivefold increase in 5-year overall survival rate compared to treatment with the chemotherapy docetaxel. Scott Gettinger, MD, of Yale...
Erratum
In the August 10, 2019, issue of The ASCO Post, a photo on page 39, in an article about the National Comprehensive Cancer Network (NCCN) Policy Summit, was incorrectly identified as Terrell Johnson, MPA, an NCCN Policy and Advocacy Fellow. We regret the error and apologize to Mr. Johnson for the...
FDA Proposes New Required Health Warnings With Images for Cigarette Packages and Advertisements
On August 15, the U.S. Food and Drug Administration (FDA) issued a proposed rule to require new health warnings on cigarette packages and in advertisements to promote greater public understanding of the negative health consequences of smoking. The proposed warnings, which feature photo-realistic...
John Hansen, MD, Transplant Expert Who Founded Volunteer Donor Registries, Dies at 76
Over the past few decades, our understanding of transplant immunology has moved from basic allograft rejection to the current molecular level that offers life-saving treatments for patients with cancer. The scientific elegance of this remarkable therapy’s arc from experimental to standard of care...
Having Cancer as a Teenager Derailed My Life Course
In 1994, I was a normal, active 15-year-old, who loved cars, sports, and rock music, especially songs from my favorite group, The Clash. In fact, it was while jubilantly dancing alone in my room to one of their tunes that I vomited into my hands, an early symptom of acute myeloid leukemia (AML). I...
A Vigorous Life Through the Prism of Impending Death
“Live while you’re living, friends,” writes Julie Yip-Williams in her memoir, The Unwinding of the Miracle: A Memoir of Life, Death, and Everything That Comes After. It was The New York Times bestseller when she died of stage IV colon cancer at the age of 42. She is the most recent of several...
Not for the Squeamish: Surgery in the 19th Century
Imagine undergoing major surgery in a grimy operating room without any form of antisepsis. That was the grim reality in the 1800s, when the ruling theory was that damage from “bad air” was responsible for infections in surgical wounds. Hospitals simply aired out the surgical wards at midday to...
Florida Cancer Specialists Welcomes Luis Carrascosa, MD
Florida Cancer Specialists & Research Institute recently announced that radiation oncologist Luis Carrascosa, MD, has joined the statewide practice. Dr. Carrascosa has privileges at Ocala Regional Medical Center, West Marion Community Hospital, and AdventHealth Ocala. Dr. Carrascosa earned his ...
Pembrolizumab in Advanced Esophageal Squamous Cell Cancer With PD-L1 Expression of CPS ≥ 10
On July 30, 2019, pembrolizumab was approved for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed cell death ligand 1 (PD-L1; Combined Positive Score [CPS] ≥ 10), as determined by a U.S. Food and Drug...
Doctor, Where Art Thou?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Nakul Singhal, MD, and Nicole Carreau, MD, Join New York Cancer & Blood Specialists
Oncologist Nakul Singhal, MD, has joined New York Cancer & Blood Specialists (NYCBS) and will be accepting new patients at the Bayside and New Hyde Park locations. NYCBS also welcomes oncologist Nicole Carreau, MD. Prior to joining NYCBS, Dr. Singhal practiced at Hackensack Meridian Health...
Steven A. Rosenberg, MD, PhD, Awarded for His Pioneering Work in Immunotherapy
The Edogawa-NICHE Committee recently announced that the 2019-Edogawa NICHE Prize has been awarded to Steven A. Rosenberg, MD, PhD, for his work in developing effective adoptive immunotherapies and genetically modified T cells. Dr. Rosenberg’s research has significantly contributed to the...
Confronting the Criticisms Facing Watson for Oncology
Over the past 2 years, IBM’s Watson for Oncology cognitive computing system, which uses artificial intelligence (AI) algorithms to generate treatment recommendations, has come under fire for allegedly not delivering on expectations to provide state-of-the-art personalized treatment for patients...
MD Anderson to Expand Proton Therapy Center
The University of Texas MD Anderson Cancer Center recently unveiled plans to expand its Proton Therapy Center. The expansion will more than double the center’s size to more than 160,000 square feet. The estimated completion of the new building is November 2023. The $159 million expansion will...
FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...
American Cancer Society Names William G. Cance, MD, Chief Medical and Scientific Officer
William G. Cance, MD, has been selected as he Chief Medical and Scientific Officer of the American Cancer Society (ACS). Dr. Cance will lead the integration of the ACS Research and Cancer Control departments, unifying its intramural and extramural research; prevention and early detection; patient...
Firing Your Patient: How to Terminate a Treatment Relationship
Many clinicians are confused by the evolving opioid prescribing guideline issued by the Centers for Disease Control and Prevention (CDC) meant to stem the rising epidemic of opioid addiction and overdose in the United States.1 Many are also worried about regulatory oversight by the U.S. Drug...
Bert Vogelstein, MD, and Irving L. Weissman, MD, Recognized for Revolutionizing Cancer Research
Two scientists, whose discoveries in stem cell and cancer cell biology have led to innovative advances in fields ranging from oncology and immunology to cancer genomics and regenerative medicine, will receive the 2019 Albany Medical Center Prize in Medicine and Biomedical Research. Bert Vogelstein, ...
Women Who Conquer Cancer: Featured Conversations
The Conquer Cancer “Your Stories” mini-podcast series shares unscripted conversations among patients, doctors, and the family and friends who conquer cancer with them. Developed by Conquer Cancer, the series also includes transcripts of conversations. In one such featured conversation, Christina...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career female researchers by funding research grants through Conquer Cancer, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, has funded 21 Young...
Stock Your Practice With ASCO Answers Materials
ASCO has created helpful resources to support your patients and their caregivers. ASCO Answers patient education materials provide trusted information on cancer types, diagnosis, treatment, side effects, and coping in three convenient formats: fact sheets, topic-specific booklets, and comprehensive ...
ASCO Welcomes 2019–2020 Leadership Development Program Participants, Education Scholars
ASCO is pleased to announce the 2019–2020 participants in its Leadership Development Program and Education Scholars Program. Leadership Development Program The ASCO Leadership Development Program, which began in 2009, is a year-long program designed to train future leaders in oncology by supporting ...
New ASCO Ethical Framework for Including Research Biopsies in Clinical Trials
ASCO has released an ethical framework for researchers on incorporating research biopsies in cancer clinical trials. The framework, published in a statement in the Journal of Clinical Oncology on July 25, provides guidance on when to include optional and mandatory biopsies based on both participant ...
2020 Fee Schedule Proposal Outlines E&M Code and MIPS Changes
On July 29, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule for the 2020 Medicare Physician Fee Schedule (MPFS) and other changes to Medicare Part B payment policies, including proposals related to the Quality Payment Program (QPP). At the same time, CMS released...
Apply by September 25 to ASCO’s Health Policy Leadership Development Program
Develop expertise in health policy, advocacy, and grassroots activity while learning valuable leadership skills—applications are open through September 25 for the 2020–2021 cycle of ASCO’s Health Policy Leadership Development Program. Oncologists have an important role to play in shaping the...
Sita Kugel, PhD, Receives Grant to Study Aggressive Type of Pancreatic Cancer
The deadly nature of most pancreatic tumors is well known, with less than 10% of patients with pancreatic ductal adenocarcinoma estimated to survive 5 years after diagnosis. Recent molecular analyses of pancreatic ductal adenocarcinoma have shown that a patient’s prognosis changes depending on the...
Nancy E. Davidson, MD, FASCO, and Jerry Radich, MD, Receive Endowed Chairs at Fred Hutchinson Cancer Research Center
Two researchers at the Fred Hutchinson Cancer Research Center in Seattle were recently awarded endowed chairs: Nancy E. Davidson, MD, FASCO, and Jerry Radich, MD. Raisbeck Endowed Chair for Collaborative Research Dr. Davidson was awarded the Raisbeck Endowed Chair for Collaborative Research at Fred ...
Primary Central Nervous System Lymphoma: Striving for a Curative Therapy
Primary central nervous system (CNS) lymphoma is a rare type of non-Hodgkin lymphoma in which standards of care have not been well established. In light of recent insights into its pathophysiology and the emergence of novel approaches, The ASCO Post asked Tracy T. Batchelor, MD, a specialist in...
CureMD Oncology Integrates NCCN Templates
The National Comprehensive Cancer Network® (NCCN®) is collaborating with CureMD to integrate the NCCN Chemotherapy Order Templates into the CureMD Oncology electronic health records. This collaboration is intended to allow for point-of-care access to treatment recommendations and order templates...
David I. Sternberg, MD, Joins Karmanos Cancer Institute
The Barbara Ann Karmanos Cancer Institute has announced that thoracic surgeon David I. Sternberg, MD, has joined its medical team. Board-certified in general and cardiothoracic surgery, and specialized in minimally invasive chest surgery, Dr. Sternberg will serve on Karmanos’ Thoracic Oncology...
Northern California Prostate Cancer Center Joins U.S. Oncology Network
The Northern California Prostate Cancer Center, an independent oncology practice serving patients with cancer throughout Santa Clara County, has joined the U.S. Oncology Network. The practice, which opened in 2009, was the first prostate-only radiation treatment center in California to obtain a...
$1 Million Gift for Epithelioid Hemangioendothelioma Research
The Epithelioid Hemangioendothelioma (EHE) Foundation and Cleveland Clinic recently received a $1 million gift from the Margie and Robert E. Petersen Foundation. The money will support EHE research conducted by Brian Rubin, MD, PhD, Chair of the Robert J. Tomsich Pathology & Laboratory Medicine ...
IU Simon Cancer Center Earns NCI’s Comprehensive Cancer Center Designation
The Indiana University Melvin and Bren Simon Cancer Center (IU Simon Cancer Center) has achieved the highest recognition from the National Cancer Institute (NCI): Comprehensive Cancer Center. With this federal designation signifying research excellence, it becomes the only NCI-designated...
NCI Community Oncology Research Program Expands to More Sites
The National Cancer Institute (NCI) has awarded 53 grants to researchers in the NCI Community Oncology Research Program (NCORP) to conduct multisite cancer clinical trials and cancer care delivery studies in their communities. In addition to 7 research hubs, these NCI grants went to 32 community...
Update on FDA-Approved CAR T-Cell Gene Therapy for B-Cell Lymphomas
On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Specifically, this treatment can be used after two or more lines of systemic therapy for diffuse...
